Canada Pension Plan Investment Board Buys Shares of 70,800 Sarepta Therapeutics, Inc. $SRPT

Key Points

• Canada Pension Plan Investment Board bought 70,800 Sarepta Therapeutics shares worth approximately $1.27 million, acquiring a stake of about 0.07%. Institutional investors collectively own 86.68% of the company.
• Analyst sentiment is mixed, with nine Buy, six Hold, and five Sell ratings; the stock carries a consensus Hold rating and an average price target of $25.06.
• Sarepta reported quarterly EPS of $0.64, exceeding the $0.22 consensus estimate, while revenue of $401.25 million fell 34.3% year over year. Shares opened at $21.03, within a 12-month range of $14.68 to $25.32.

Canada Pension Plan Investment Board purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 70,800 shares of the biotechnology company's stock, valued at approximately $1,272,000. Canada Pension Plan Investment Board owned approximately 0.07% of Sarepta Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Kestra Advisory Services LLC acquired a new stake in Sarepta Therapeutics in the 4th quarter valued at about $25,000. iSAM Funds UK Ltd purchased a new position in Sarepta Therapeutics during the 3rd quarter valued at about $25,000. Meeder Asset Management Inc. acquired a new position in Sarepta Therapeutics during the second quarter worth about $27,000. Ancora Advisors LLC raised its position in Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Allworth Financial LP lifted its holdings in shares of Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 1,721 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on SRPT. Weiss Ratings lowered shares of Sarepta Therapeutics from a "sell (d)" rating to a "sell (e+)" rating in a research report on Wednesday, August 19th. Piper Sandler cut their price objective on Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating for the company in a research report on Thursday, July 9th. HC Wainwright reaffirmed a "buy" rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 28th. Wall Street Zen cut Sarepta Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Finally, Zacks Research upgraded Sarepta Therapeutics from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 12th. Nine analysts have rated the stock with a Buy rating, six have assigned a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $25.06.

Sarepta Therapeutics Trading Up 0.8%

Shares of SRPT stock opened at $21.03 on Tuesday. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of -7.25, a PEG ratio of 0.31 and a beta of 0.24. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average price of $17.79 and a 200 day moving average price of $18.34. Sarepta Therapeutics, Inc. has a twelve month low of $14.68 and a twelve month high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.42. The company had revenue of $401.25 million for the quarter, compared to analysts' expectations of $366.39 million. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The firm's revenue for the quarter was down 34.3% compared to the same quarter last year. During the same period last year, the company earned $2.02 EPS. Research analysts forecast that Sarepta Therapeutics, Inc. will post 3.43 earnings per share for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source